Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Pharmacopsychiatry. 2022 Jan;55(1):24-29. doi: 10.1055/a-1686-9620. Epub 2021 Dec 7.
Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer's disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer's disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications.
选择性 5-羟色胺再摄取抑制剂（SSRIs）是安全且广泛应用于多种适应证的药物，包括抑郁障碍、焦虑症和慢性疼痛。除了抑制 5-羟色胺转运体，这些药物在许多系统中还具有广谱特性。它们在癌症、阿尔茨海默病和感染过程中的作用已经得到研究。COVID-19 大流行凸显了重新利用已上市药物的重要性。我们对 SSRIs 的药物再利用的现有证据和正在进行的研究进行了叙述性综述，重点关注免疫调节、抗增殖和神经保护活性。SSRIs 可能具有临床应用价值，可作为多种疾病的重新定位药物，包括但不限于 COVID-19、阿尔茨海默病和肿瘤性疾病。需要进一步的研究，特别是随机对照试验，以确认 SSRIs 在新适应证中的效用。
